Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) EBT (2016 - 2025)

Historic EBT for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to -$103.4 million.

  • Agios Pharmaceuticals' EBT fell 11033.26% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$411.9 million, marking a year-over-year decrease of 15687.77%. This contributed to the annual value of $718.0 million for FY2024, which is 30391.75% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' EBT stood at -$103.4 million, which was down 11033.26% from -$112.5 million recorded in Q2 2025.
  • Agios Pharmaceuticals' EBT's 5-year high stood at $1.0 billion during Q3 2024, with a 5-year trough of -$112.5 million in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' median EBT value was -$91.3 million (recorded in 2023), while the average stood at -$35.8 million.
  • In the last 5 years, Agios Pharmaceuticals' EBT soared by 119613.57% in 2024 and then tumbled by 11033.26% in 2025.
  • Over the past 5 years, Agios Pharmaceuticals' EBT (Quarter) stood at -$98.6 million in 2021, then rose by 5.98% to -$92.7 million in 2022, then dropped by 3.51% to -$95.9 million in 2023, then fell by 9.86% to -$105.4 million in 2024, then increased by 1.87% to -$103.4 million in 2025.
  • Its EBT stands at -$103.4 million for Q3 2025, versus -$112.5 million for Q2 2025 and -$90.5 million for Q1 2025.